 |
English
|
正體中文
|
简体中文
|
全文筆數/總筆數 : 45401/58577 (78%)
造訪人次 : 2510073
線上人數 : 292
|
|
|
資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://libir.tmu.edu.tw/handle/987654321/64828
|
| 題名: | Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance |
| 作者: | 楊培銘
Hsieh, Y. Y., Du, J. L., & Yang, P. M. |
| 貢獻者: | 癌症生物學與藥物研發研究所 |
| 關鍵詞: | colorectal cancer;connectivity map;drug repositioning;drug resistance;microtubule-targeting agent;polypharmacology. |
| 日期: | 2024-02 |
| 上傳時間: | 2024-12-04 14:05:38 (UTC+8) |
| 摘要: | Microtubule-targeting agents represent one of the most successful classes of anticancer agents. However, the development of drug resistance and the appearance of adverse effects hamper their clinical implementation. Novel microtubule-targeting agents without such limitations are urgently needed. By employing a gene expression-based drug repositioning strategy, this study identifies VU-0365114, originally synthesized as a positive allosteric modulator of human muscarinic acetylcholine receptor M5 (M5 mAChR), as a novel type of tubulin inhibitor by destabilizing microtubules. VU-0365114 exhibits a broad-spectrum in vitro anticancer activity, especially in colorectal cancer cells. A tumor xenograft study in nude mice shows that VU-0365114 slowed the in vivo colorectal tumor growth. The anticancer activity of VU-0365114 is not related to its original target, M5 mAChR. In addition, VU-0365114 does not serve as a substrate of multidrug resistance (MDR) proteins, and thus, it can overcome MDR. Furthermore, a kinome analysis shows that VU-0365114 did not exhibit other significant off-target effects. Taken together, our study suggests that VU-0365114 primarily targets microtubules, offering potential for repurposing in cancer treatment, although more studies are needed before further drug development. |
| 關聯: | Molecular oncology, 18(2), 386–414 |
| 描述: | 【112-2 升等】臺北醫學大學教師升等專門著作
職別：專任
送審等級：教授
著作送審 |
| 附註: | 代表著作名稱：《Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance》
? 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. |
| 資料類型: | article |
| 顯示於類別: | [教師升等送審著作] 112
[癌症生物學與藥物研發研究所] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 48 | 檢視/開啟 |
|
在TMUIR中所有的資料項目都受到原著作權保護.
|
